Myeloma Research News is a digital platform intended to provide the myeloma community with the most recent news and information on the disease.
All articles on Myeloma Research News are original content produced by in-house writers and editors. Occasionally, we seek the opinion of outside experts for interviews and Q&As.
The publishing team at Myeloma Research News is made up of science writers and editors, most of whom have PhDs in the life sciences and veteran journalists. Together, they ensure that all content published on Myeloma Research News is relevant, accurate, informative, relatable, and easy to understand.
Our daily reporting includes:
- news stories detailing the latest research and information on myeloma
- feature stories and community profiles
- in-depth reports
- interviews and Q&As with leading experts
- comprehensive conference coverage
- resource and informational pages
Editorial and fact-checking process
Each piece of content is carefully selected and written with the myeloma community in mind. Sources for news stories and resource pages include peer-reviewed studies, press releases, announcements, interviews, webinars, and conference sessions, among others. All articles go through a stringent fact-checking and editing process to ensure they are accurate, objective, comprehensive, and well-explained.
Myeloma Research News upholds the highest levels of journalistic integrity, with the goal of maintaining objectivity and transparency. As such, editorial content published on the website is not influenced in any way by its advertisers. While relevant and responsible sponsorships are accepted, editorial content is produced independently of advertising and is not subject to undue influence from either external or internal factors.
Advertising content is clearly marked and separated from editorial content throughout the website. Revenue generated from advertising and sponsorships allows us to continue our mission of informing and empowering members of the myeloma community.
For more information, see our Advertising Policy.
About BioNews, Inc.
BioNews, Inc., is independently owned and operated. It does not produce, market, or sell any product intended to treat, manage, or diagnose myeloma or any other condition.
The focus of BioNews is to empower patients living with rare disease. We provide a safe space for those affected by rare diseases to form meaningful and impactful relationships.
Our ability to connect with others allows us to provide each individual with understanding, empathy, and support. At BioNews, we make a promise to our rare disease communities to deliver trustworthy information to help educate, engage, and champion the patient voice.
For more information, see our Culture page.